Edition:
United States

ImmunoGen Inc (IMGN.O)

IMGN.O on Nasdaq

2.33USD
19 Jul 2019
Change (% chg)

$0.02 (+0.87%)
Prev Close
$2.31
Open
$2.30
Day's High
$2.38
Day's Low
$2.30
Volume
1,081,026
Avg. Vol
3,403,691
52-wk High
$10.39
52-wk Low
$1.76

About

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor... (more)

Overall

Beta: 2.22
Market Cap(Mil.): $768.71
Shares Outstanding(Mil.): 112.22
Dividend: --
Yield (%): --

Financials

  IMGN.O Industry Sector
P/E (TTM): -- 69.41 32.67
EPS (TTM): -1.21 -- --
ROI: -63.15 8.94 14.49
ROE: -- 10.07 15.79

ImmunoGen drug fails cancer study, shares slide 40 percent

U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study, driving its shares more than 40 percent lower on Friday.

Mar 01 2019

ImmunoGen's ovarian cancer drug fails in late-stage study

March 1 U.S. drug developer ImmunoGen Inc said on Friday its experimental ovarian cancer drug failed to meet the main goal of a late-stage study.

Mar 01 2019

Earnings vs. Estimates